椎动脉狭窄血管内治疗的现状和挑战  

Status quo and challenges of endovascular treatment in vertebral artery stenosis

作　　者：陈大伟 石进 Chen Dawei;Shi Jin(Department of Neurology,Air Force Medical Center of Chinese People's Liberation Army,Beijing 100142,China)

机构地区：[1]中国人民解放军空军特色医学中心神经内科,北京100142

出　　处：《中华神经医学杂志》2024年第11期1081-1085,共5页Chinese Journal of Neuromedicine

基　　金：空军特色医学中心临床研究项目(2021LC002)。

摘　　要：随着医学影像学技术的发展,椎动脉狭窄检出率呈上升趋势。症状性椎动脉狭窄即使经过严格的药物治疗,脑卒中复发率仍较高。现阶段,血管内治疗方式在症状性椎动脉狭窄中的应用越来越广泛,但其疗效仍缺乏高等级循证医学证据,术后再狭窄率亦较高。故本文围绕血管内治疗的有效性、围手术期风险、远期术后再狭窄及其防治对策、脑卒中复发高危患者筛选等问题进行论述,以期进一步提高该类患者的临床获益。With developing medical imaging,increased detection rate of vertebral artery stenosis is noted.Stroke recurrence rate is still high even after strict medical treatment for symptomatic vertebral artery stenosis.At present,endovascular treatment is more and more widely used in symptomatic vertebral artery stenosis(accompanying high postoperative restenosis rate),but high-level evidence-based medical evidence for its efficacy is needed.Therefore,this article focuses on the effectiveness of endovascular treatment,perioperative risk,long-term postoperative restenosis,prevention and treatment strategies of restenosis,and screening of patients with high risk of stroke recurrence,in order to further improve the clinical benefits of these patients.

关 键 词：椎动脉狭窄 血管内治疗 脑卒中 血管再狭窄 

分 类 号：R743[医药卫生—神经病学与精神病学]